CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Theravance Biopharma, Inc. - TBPH CFD

9.50
0.74%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Theravance Biopharma Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 9.45
Open* 9.34
1-Year Change* 6.02%
Day's Range* 9.34 - 9.56
52 wk Range 7.53-13.17
Average Volume (10 days) 1.30M
Average Volume (3 months) 16.32M
Market Cap 714.75M
P/E Ratio -100.00K
Shares Outstanding 67.37M
Revenue 51.64M
EPS -1.10
Dividend (Yield %) N/A
Beta 0.53
Next Earnings Date Feb 21, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 29, 2024 9.45 0.02 0.21% 9.43 9.61 9.31
Feb 28, 2024 9.38 -0.10 -1.05% 9.48 9.69 9.28
Feb 27, 2024 9.65 0.53 5.81% 9.12 9.96 8.79
Feb 26, 2024 9.19 0.38 4.31% 8.81 9.20 8.69
Feb 23, 2024 8.94 0.48 5.67% 8.46 8.96 8.31
Feb 22, 2024 8.63 0.12 1.41% 8.51 8.76 8.41
Feb 21, 2024 8.73 0.00 0.00% 8.73 8.90 8.59
Feb 20, 2024 8.88 0.25 2.90% 8.63 8.96 8.63
Feb 16, 2024 8.76 0.30 3.55% 8.46 8.84 8.44
Feb 15, 2024 8.63 0.18 2.13% 8.45 8.71 8.45
Feb 14, 2024 8.42 0.19 2.31% 8.23 8.46 8.20
Feb 13, 2024 8.32 -0.08 -0.95% 8.40 8.45 8.21
Feb 12, 2024 8.56 0.23 2.76% 8.33 8.60 8.26
Feb 9, 2024 8.53 0.31 3.77% 8.22 8.56 8.20
Feb 8, 2024 8.20 -0.27 -3.19% 8.47 8.47 8.18
Feb 7, 2024 8.47 -0.33 -3.75% 8.80 8.80 8.44
Feb 6, 2024 8.76 0.09 1.04% 8.67 8.90 8.51
Feb 5, 2024 8.79 -0.04 -0.45% 8.83 8.87 8.58
Feb 2, 2024 8.86 -0.16 -1.77% 9.02 9.07 8.73
Feb 1, 2024 9.02 -0.15 -1.64% 9.17 9.42 9.00

Theravance Biopharma, Inc. Events

Time (UTC) Country Event
Tuesday, March 5, 2024

Time (UTC)

15:30

Country

KY

Event

Theravance Biopharma Inc at TD Cowen Health Care Conference
Theravance Biopharma Inc at TD Cowen Health Care Conference

Forecast

-

Previous

-
Wednesday, May 1, 2024

Time (UTC)

11:00

Country

KY

Event

Theravance Biopharma Inc Annual Shareholders Meeting
Theravance Biopharma Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Monday, May 6, 2024

Time (UTC)

10:59

Country

KY

Event

Q1 2024 Theravance Biopharma Inc Earnings Release
Q1 2024 Theravance Biopharma Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 51.346 55.311 71.857 73.414 60.37
Revenue 51.346 55.311 71.857 73.414 60.37
Cost of Revenue, Total 0 0.715
Gross Profit 73.414 59.655
Total Operating Expense 146.337 313.095 369.484 325.329 299.121
Selling/General/Admin. Expenses, Total 67.073 100.673 109.289 106.245 97.058
Research & Development 63.392 192.28 260.195 219.084 201.348
Operating Income -94.991 -257.784 -297.627 -251.915 -238.751
Interest Income (Expense), Net Non-Operating 2.176 -7.438 -4.106 10.238 12.666
Net Income Before Taxes -92.815 -265.222 -303.343 -241.677 -226.085
Net Income After Taxes -92.824 -265.071 -294.823 -236.455 -215.524
Net Income Before Extra. Items -92.824 -265.071 -294.823 -236.455 -215.524
Net Income 872.132 -199.426 -278.017 -236.455 -215.524
Income Available to Common Excl. Extra. Items -92.824 -265.071 -294.823 -236.455 -215.524
Income Available to Common Incl. Extra. Items 872.132 -199.426 -278.017 -236.455 -215.524
Diluted Net Income 872.132 -199.426 -278.017 -236.455 -215.524
Diluted Weighted Average Shares 73.591 69.461 62.345 55.61 53.969
Diluted EPS Excluding Extraordinary Items -1.26135 -3.81611 -4.7289 -4.25202 -3.99348
Diluted Normalized EPS -1.12116 -3.62763 -4.7289 -4.25202 -3.99348
Unusual Expense (Income) 15.872 20.142 0 0 0
Total Extraordinary Items 964.956 65.645 16.806
Other, Net 0 0 -1.61
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 13.749 10.417 14.649 12.451 11.05
Revenue 13.749 10.417 14.649 12.451 11.05
Total Operating Expense 29.872 35.329 32.08 29.687 34.151
Selling/General/Admin. Expenses, Total 19.278 19.183 15.968 16.277 16.222
Research & Development 9.425 14.572 14.701 9.867 14.924
Operating Income -16.123 -24.912 -17.431 -17.236 -23.101
Interest Income (Expense), Net Non-Operating 1.936 2.429 3.172 1.213 0.303
Net Income Before Taxes -14.187 -22.483 -14.259 -16.023 -22.798
Net Income After Taxes -15.645 -22.088 -14.256 -16.023 -22.793
Net Income Before Extra. Items -15.645 -22.088 -14.256 -16.023 -22.793
Net Income -15.645 -22.088 -10.362 916.631 -8.191
Income Available to Common Excl. Extra. Items -15.645 -22.088 -14.256 -16.023 -22.793
Income Available to Common Incl. Extra. Items -15.645 -22.088 -10.362 916.631 -8.191
Diluted Net Income -15.645 -22.088 -10.362 916.631 -8.191
Diluted Weighted Average Shares 56.682 62.934 67.33 75.515 76.27
Diluted EPS Excluding Extraordinary Items -0.27601 -0.35097 -0.21173 -0.21218 -0.29885
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.26261 -0.33471 -0.19811 -0.16527 -0.27324
Unusual Expense (Income) 1.169 1.574 1.411 3.543 3.005
Total Extraordinary Items 0 0 3.894 932.654 14.602
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 353.464 249.87 393.341 338.488 532.823
Cash and Short Term Investments 327.484 173.465 292.941 280.831 505.276
Cash & Equivalents 298.172 89.959 81.467 58.064 378.021
Short Term Investments 29.312 83.506 211.474 222.767 127.255
Total Receivables, Net 16.785 57.599 69.667 50.57 10.673
Accounts Receivable - Trade, Net 16.785 14.065 15.868 11.996 10.673
Total Inventory 0
Prepaid Expenses 9.195 18.806 30.733 7.087 16.874
Total Assets 607.4 374.819 469.057 408.826 560.235
Property/Plant/Equipment, Total - Net 52.001 53.347 59.682 59.248 13.176
Property/Plant/Equipment, Total - Gross 84.837 91.839 105.49 106.816 62.871
Accumulated Depreciation, Total -32.836 -38.492 -45.808 -47.568 -49.695
Long Term Investments 0 67.537 12.75 4.985 11.869
Other Long Term Assets, Total 201.935 4.065 3.284 2.423 2.367
Total Current Liabilities 28.715 58.587 123.571 111.703 98.554
Accounts Payable 1.554 3.098 6.775 4.758 9.028
Accrued Expenses 27.137 38.451 85.939 65.519 46.124
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.024 0.098 11.523 31.575 43.402
Total Liabilities 165.6 713.392 772.808 632.666 611.824
Total Long Term Debt 0 599.394 599.836 445.19 454.353
Long Term Debt 0 599.394 599.836 445.19 454.353
Other Liabilities, Total 136.885 55.411 49.401 75.773 58.917
Total Equity 441.8 -338.573 -303.751 -223.84 -51.589
Common Stock 0.001 0.001 0.001 0.001 0.001
Additional Paid-In Capital 1295.72 1387.47 1222.82 1024.61 960.721
Retained Earnings (Accumulated Deficit) -853.911 -1726.04 -1526.62 -1248.6 -1012.15
Other Equity, Total -0.015 0 0.047 0.145 -0.166
Total Liabilities & Shareholders’ Equity 607.4 374.819 469.057 408.826 560.235
Total Common Shares Outstanding 65.227 74.435 64.328 57.015 55.681
Note Receivable - Long Term 0 3.682 0
Current Port. of LT Debt/Capital Leases 0 16.94 19.334 9.851
Preferred Stock - Non Redeemable, Net 0 0 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 161.69 192.003 261.338 353.464 511.718
Cash and Short Term Investments 134.003 167.451 241.263 327.484 486.832
Cash & Equivalents 71.685 105.596 187.665 298.172 418.538
Short Term Investments 62.318 61.855 53.598 29.312 68.294
Total Receivables, Net 17.057 15.796 12.27 16.785 14.114
Accounts Receivable - Trade, Net 17.057 15.796 12.27 16.785 14.114
Prepaid Expenses 10.63 8.756 7.805 9.195 10.772
Total Assets 413.59 446.63 538.55 607.4 763.496
Property/Plant/Equipment, Total - Net 46.864 48.006 51.307 52.001 51.876
Long Term Investments 18.776 0 0
Other Long Term Assets, Total 205.036 206.621 207.129 201.935 199.902
Total Current Liabilities 25.368 24.546 26.184 28.715 142.132
Accounts Payable 2.368 1.569 2.663 1.554 5.337
Accrued Expenses 22.976 22.953 23.497 27.137 16.221
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0
Other Current Liabilities, Total 0.024 0.024 0.024 0.024 120.574
Total Liabilities 167.46 166.469 167.991 165.6 282.918
Total Long Term Debt 0 0 0 0 0
Long Term Debt 0 0
Other Liabilities, Total 142.092 141.923 141.807 136.885 140.786
Total Equity 246.13 280.161 370.559 441.8 480.578
Common Stock 0.001 0.001 0.001 0.001 0.001
Additional Paid-In Capital 1146.95 1172.09 1246.51 1295.72 1324.25
Retained Earnings (Accumulated Deficit) -900.594 -891.644 -875.999 -853.911 -843.549
Other Equity, Total -0.225 -0.286 0.051 -0.015 -0.121
Total Liabilities & Shareholders’ Equity 413.59 446.63 538.55 607.4 763.496
Total Common Shares Outstanding 50.819 53.694 60.542 65.227 67.366
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -92.824 -199.426 -278.017 -236.455 -215.524
Cash From Operating Activities -186.991 -207.858 -250.403 -238.197 -112.867
Cash From Operating Activities 3.716 5.912 6.798 6.441 3.166
Non-Cash Items -140.233 25.24 60.278 37.217 40.062
Cash Taxes Paid 117.966 4.089 0.014 0.022 -7.316
Cash Interest Paid 22.244 39.029 24.024 26.178 7.475
Changes in Working Capital 42.35 -39.584 -39.462 -45.4 59.429
Cash From Investing Activities 1154.01 124.494 10.721 -83.051 176.708
Capital Expenditures -0.572 -3.406 -6.616 -3.176 -7.24
Other Investing Cash Flow Items, Total 1154.58 127.9 17.337 -79.875 183.948
Cash From Financing Activities -758.806 91.86 263.085 1.291 225.2
Financing Cash Flow Items 5.077 3.466 3.701 3.474 4.173
Issuance (Retirement) of Stock, Net -132.28 99.124 131.527 -0.031 -8.414
Issuance (Retirement) of Debt, Net -631.603 -10.73 127.857 -2.152 229.441
Net Change in Cash 208.212 8.496 23.403 -319.957 289.041
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -22.088 -92.824 -78.568 -34.137 -25.946
Cash From Operating Activities -11.221 -186.991 -62.936 -40.799 -26.069
Cash From Operating Activities 0.625 3.716 3.057 2.402 1.141
Non-Cash Items 7.953 -140.233 29.781 -7.134 0.786
Cash Taxes Paid -0.007 117.966 0.026 0.025 0
Cash Interest Paid 0 22.244 22.244 15.127 4.613
Changes in Working Capital 2.289 42.35 -17.206 -1.93 -2.05
Cash From Investing Activities -43.046 1154.01 1114.85 39.439 31.924
Capital Expenditures -0.938 -0.572 -0.306 -0.363 -0.25
Other Investing Cash Flow Items, Total -42.108 1154.58 1115.15 39.802 32.174
Cash From Financing Activities -56.24 -758.806 -723.334 -1.308 -1.448
Issuance (Retirement) of Stock, Net -56.24 -132.28 -96.494 -1.795 -1.448
Issuance (Retirement) of Debt, Net -631.603 -631.603 0 0
Net Change in Cash -110.507 208.212 328.578 -2.668 4.407
Financing Cash Flow Items 5.077 4.763 0.487
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Weiss Asset Management Hedge Fund 14.1197 7457060 0 2023-08-09 HIGH
The Baupost Group, L.L.C. Investment Advisor/Hedge Fund 14.0481 7419226 -3000000 2023-06-30
Madison Avenue Partners LP Hedge Fund 13.2774 7012226 0 2023-06-30 MED
BlackRock Institutional Trust Company, N.A. Investment Advisor 8.3151 4391467 -91311 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.965 4206562 -1407770 2023-06-30 LOW
Odre 2005 SL Corporation 7.779 4108318 4108318 2022-03-18 LOW
Irenic Capital Management LP Hedge Fund 5.2278 2760948 -3100 2023-06-30 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 3.4878 1841997 387730 2023-06-30 LOW
Park West Asset Management LLC Hedge Fund 3.2582 1720751 -179452 2023-06-30 MED
Newtyn Management, LLC Hedge Fund 3.1062 1640456 109441 2023-06-30 MED
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.7972 1477288 66280 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 2.2071 1165662 -20347 2023-06-30 LOW
Winningham (Rick E) Individual Investor 2.1612 1141415 -15804 2023-08-20 LOW
Fidelity Management & Research Company LLC Investment Advisor 1.8269 964824 -749565 2023-06-30 LOW
Pictet Asset Management (Japan) Ltd. Investment Advisor 1.3638 720258 361576 2023-04-30 LOW
D. E. Shaw & Co., L.P. Hedge Fund 1.3522 714114 -300879 2023-06-30 MED
Oasis Management Company Ltd. Investment Advisor/Hedge Fund 1.2237 646273 23997 2023-06-30 LOW
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 1.169 617366 -430757 2023-06-30 MED
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.0327 545427 0 2022-12-31 LOW
Opaleye Management Inc. Hedge Fund 1.0291 543500 -2804 2023-06-30 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Theravance Biopharma, Inc. Company profile

About Theravance Biopharma Inc

Theravance Biopharma, Inc. is a diversified biopharmaceutical company, which is primarily focused on the discovery, development and commercialization of organ-selective medicines. The Company develops transformational medicines to improve the lives of patients suffering from serious illnesses. The Company's research is focused in the areas of inflammation and immunology. It applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The Company is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Theravance Biopharma Inc revenues decreased 23% to $55.3M. Net loss decreased 28% to $199.4M. Revenues reflect U.S. segment decrease of 21% to $55.3M, Europe segment decrease of 98% to $38K. Lower net loss reflects Research and development - bal decrease of 27% to $166.6M (expense), Selling, general and administrative -bal decrease of 55% to $31M (expense).

Industry: Pharmaceuticals (NEC)

Ugland House, South Church Street
GEORGE TOWN
GRAND CAYMAN KY1-1104
KY

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

XRP/USD

0.60 Price
-0.850% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

80.34 Price
+2.790% 1D Chg, %
Long position overnight fee 0.0259%
Short position overnight fee -0.0478%
Overnight fee time 22:00 (UTC)
Spread 0.030

BTC/USD

61,575.50 Price
-0.230% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

18,193.60 Price
+0.850% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading